Your session is about to expire
← Back to Search
Anti-metabolites
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Phase 1 & 2
Waitlist Available
Research Sponsored by Cyclacel Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Approved for 5 Other Conditions
Summary
This is a combination study to evaluate sapacitabine administered in alternating cycles with decitabine in previously untreated Acute Myeloid Leukemia (AML) or concomitantly with venetoclax in previously treated AML or MDS
Eligible Conditions
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Trial Design
2Treatment groups
Experimental Treatment
Group I: sapacitabine/venetoclax (Part 2 - recruiting)Experimental Treatment1 Intervention
sapacitabine will be administered concomitantly with venetoclax
Group II: Sapacitabine/decitabine (Part 1 - completed)Experimental Treatment1 Intervention
decitabine will be administered in alternating cycles with sapacitabine
Find a Location
Who is running the clinical trial?
Cyclacel Pharmaceuticals, Inc.Lead Sponsor
19 Previous Clinical Trials
2,068 Total Patients Enrolled
M.D. Anderson Cancer CenterOTHER
3,071 Previous Clinical Trials
1,803,138 Total Patients Enrolled
Hagop M Kantarjian, MDStudy ChairM.D. Anderson Cancer Center
4 Previous Clinical Trials
365 Total Patients Enrolled